Evidence map›Paper›PMID 37800633›Full record

ReviewChronic respiratory disease

How can the findings of the EMAX trial on long-acting bronchodilation in chronic obstructive pulmonary disease be applied in the primary care setting?

Edward M Kerwin, Paul W Jones, Leif H Bjermer, François Maltais, Isabelle H Boucot, Ian P Naya, David A Lipson, Chris Compton, Lee Tombs, Claus F Vogelmeier

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Chronic respiratory disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 4 countries.

Edward M KerwinClinical Trials Department, Altitude Clinical Consulting and Clinical Research Institute of Southern Oregon, Medford, OR, USA.ORCID 0000-0002-1697-9036
Paul W JonesGSK, Brentford, UK.
Leif H BjermerDepartment of Clinical Sciences, Respiratory Medicine and Allergology, Lund University, Lund, Sweden.
François MaltaisCentre de Pneumologie, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Québec, QC, Canada.
Isabelle H BoucotGSK, Brentford, UK.
Ian P NayaGSK, Brentford, UK.
David A LipsonRespiratory Clinical Sciences, GSK, Collegeville, PA, USA.ORCID 0000-0001-6732-4593
Chris ComptonGSK, Brentford, UK.
Lee TombsPrecise Approach Ltd, Contingent Worker on Assignment at GSK, Stockley Park West, Uxbridge, UK.
Claus F VogelmeierDepartment of Medicine, Pulmonary and Critical Care Medicine, University Medical Centre Giessen and Marburg, Philipps-Universität Marburg, Marburg, Germany.
Clinical Research Institute · USGlaxoSmithKline (United States) · USInstitut universitaire de cardiologie et de pneumologie de Québec · CALund University · SEPhilipps University of Marburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This review addresses outstanding questions regarding initial pharmacological management of chronic obstructive pulmonary disease (COPD). Optimizing initial treatment improves clinical outcomes in symptomatic patients, including those with low exacerbation risk. Long-acting muscarinic antagonist/long-acting β

Indexed as

Adrenergic beta-2 Receptor AgonistsPulmonary Disease, Chronic ObstructiveAdministration, InhalationBronchodilator AgentsClinical Trials as TopicHumansPrimary Health CareAdrenergic beta-2 Receptor AgonistsBronchodilator Agentsinitial maintenance therapylong-acting bronchodilatorslong-acting muscarinic antagonist/long-acting β2-agonist dual therapyprimary careSymptomatic chronic obstructive pulmonary disease

Identifiers

PMID37800633
PMCPMC10903204
OpenAlexW4387392283

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.